INSANE: Are wall street analysts predicting biogen stock will climb or sink - The Real Truth

Cambridge, Massachusetts-based Biogen Inc. (BIIB) discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. With a market cap of $23 billion, the company’s products address diseases such as multiple sclerosis, non-hodgkin's lymphoma, rheumatoid arthritis, crohn's disease, and psoriasis.

Shares of this leading biotechnology company have significantly underperformed the broader market over the past year. BIIB has declined 31.7% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 31%. In 2024, BIIB stock is down 39%, compared to the SPX’s 25.2% rise on a YTD basis.